RankAlpha logo
Back to Rankings

REVB

Revelation BiosciencesB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The earnings follow-up modestly improves the monitoring setup only if investors accept that the May 7 8-K financial-results update and ongoing AKI study preparation can bridge to a credible 2026 trial-start milestone [#8-K-2026-05-07] [#10-K-2026-02-26].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
AKI study-start timing remains uncertain; preparation for a study is not the same as trial initiation or enrollment.
Momentum
86
Value
57
Sentiment
30
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.85 · Bull $1.40 · Bear $0.45
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $53.00
Why
Momentum86 · Δ7d -
Value57 · Δ7d +0.1
Sentiment30 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
86
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.3
Sentiment
30
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 86.3 / Value 57.3 / Sentiment 30.3

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$4.14M
Beta
-0.11
Shares Out
5.92M
P/E (TTM) · Derived
-0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.07
Rev YoY
-
EPS YoY
+95.6%
Gross Margin
-
Op Margin
-
Net Debt
-$6.5M
Current Ratio
6.92
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology